COVID 19 in Hypertensive and Non-hypertensive Patients: A Descriptive Comparative Study
DOI:
https://doi.org/10.31674/mjn.2022.v14i01.003Abstract
Background: Corona virus disease 2019 (COVID-19) is respiratory disorder, which is major public health concern. The incidence of COVID-19 is increasing day by day with multiple variants. The infection spread in more than 213 countries with more than 219 million cases reported and 4.5 million deaths recorded till date. The fatality rate of COVID is 4.1% in china, 12.8% in Italy, 10.2% in Spain, 3.9% in USA, 2.3% in Germany, 1.09% in India and 2% in Pakistan. Objectives: The purpose of this study to assess the percentage of hypertensive people who got the COVID 19. Methodology: Patients with confirmed COVID positive, admitted in hospital or home quarantined from different areas of Punjab province between November 2020 and April 2021 and willing to fill the questionnaire were included in the study. Hospitalized patients were admitted with specific presentation of acute respiratory distress and SARS COV-2 positive. Qualitative data collection was done through questionnaire. Only 200 true positive of COVID-19 patients agreed to fill the questionnaire. All 200 patients included both hypertensive and non-hypertensive histories. Results: Hypertensive patients have higher chances to get COVID 19 infection. In patients with hypertension and COVID-19 morbidity was 2.1%, in which more than 1.5% patients had underlying diseases. Patients age range from 35.5 years to 70 years. Conclusion: Hypertension increases the risk of COVID 19 and showed high mortality.
Keywords:
Hypertension, COVID, RespirationDownloads
References
Alam, M. R., Kabir, M. R., & Reza, S. (2021). Comorbidities might be a risk factor for the incidence of COVID-19: Evidence from a web-based survey. Preventive Medicine Reports, 21, 101319. https://doi.org/https://doi.org/10.1016/j.pmedr.2021.101319
Batiha, G. E., Gari, A., Elshony, N., Shaheen, H. M., Abubakar, M. B., Adeyemi, S. B., & Al-Kuraishy, H. M. (2021). Hypertension and its management in COVID-19 patients: The assorted view. International journal of cardiology. Cardiovascular Risk and Prevention, 11, 200121. https://doi.org/10.1016/j.ijcrp.2021.200121
Bourgonje, A. R., Abdulle, A. E., Timens, W., Hillebrands, J. L., Navis, G. J., Gordijn, S. J., Bolling, M. C., Dijkstra, G., Voors, A. A., Osterhaus, A. D., van der Voort, P. H., Mulder, D. J., & van Goor, H. (2020). Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). The Journal of Pathology, 251(3), 228–248. https://doi.org/10.1002/path.5471
Dandachi, D., Geiger, G., Montgomery, M. W., Karmen-Tuohy, S., Golzy, M., Antar, A. A., ... & Chow, J. (2021). Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019. Clinical Infectious Diseases, 73(7), e1964-e1972. https://doi.org/10.1093/cid/ciaa1339
El Bcheraoui, C., Memish, Z. A., Tuffaha, M., Daoud, F., Robinson, M., Jaber, S., Mikhitarian, S., Al Saeedi, M., AlMazroa, M. A., Mokdad, A. H., & Al Rabeeah, A. A. (2014). Hypertension and its associated risk factors in the kingdom of saudi arabia, 2013: a national survey. International Journal of Hypertension, 2014, 564679. https://doi.org/10.1155/2014/564679
Elezkurtaj, S., Greuel, S., Ihlow, J., Michaelis, E. G., Bischoff, P., Kunze, C. A., Sinn, B. V., Gerhold, M., Hauptmann, K., Ingold-Heppner, B., Miller, F., Herbst, H., Corman, V. M., Martin, H., Radbruch, H., Heppner, F. L., & Horst, D. (2021). Causes of death and comorbidities in hospitalized patients with COVID-19. Scientific Reports, 11(1), 4263. https://doi.org/10.1038/s41598-021-82862-5
Emami, A., Javanmardi, F., Akbari, A., Kojuri, J., Bakhtiari, H., Rezaei, T., ... & Falahati, F. (2021). Survival rate in hypertensive patients with COVID-19. Clinical and Experimental Hypertension, 43(1), 77-80. https://doi.org/10.1080/10641963.2020.1812624
Gupta, R., Ghosh, A., Singh, A. K., & Misra, A. (2020). Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes & Metabolic Syndrome, 14(3), 211. https://doi.org/10.1016/j.dsx.2020.03.002
Huang, S., Wang, J., Liu, F., Liu, J., Cao, G., Yang, C., ... & Xiong, B. (2020). COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertension Research, 43(8), 824-831. https://doi.org/10.1038/s41440-020-0485-2
Ji, W., Huh, K., Kang, M., Hong, J., Bae, G. H., Lee, R., Na, Y., Choi, H., Gong, S. Y., Choi, Y. H., Ko, K. P., Im, J. S., & Jung, J. (2020). Effect of Underlying Comorbidities on the Infection and Severity of COVID-19 in Korea: a Nationwide Case-Control Study. Journal of Korean Medical Science, 35(25), e237–e237. https://doi.org/10.3346/jkms.2020.35.e237
Mahajan, K., & Chandra, K. S. (2020). Cardiovascular comorbidities and complications associated with coronavirus disease 2019. Medical Journal Armed Forces India, 76(3), 253–260. https://doi.org/https://doi.org/10.1016/j.mjafi.2020.05.004
Mithal, A., Jevalikar, G., Sharma, R., Singh, A., Farooqui, K. J., Mahendru, S., Krishnamurthy, A., Dewan, A., & Budhiraja, S. (2021). High prevalence of diabetes and other comorbidities in hospitalized patients with COVID-19 in Delhi, India, and their association with outcomes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15(1), 169–175. https://doi.org/https://doi.org/10.1016/j.dsx.2020.12.029
Ni, W., Yang, X., Yang, D., Bao, J., Li, R., Xiao, Y., Hou, C., Wang, H., Liu, J., Yang, D., Xu, Y., Cao, Z., & Gao, Z. (2020). Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Critical Care (London, England), 24(1), 422. https://doi.org/10.1186/s13054-020-03120-0
Peng, C., Wang, H., Guo, Y. F., Qi, G. Y., Zhang, C. X., Chen, T., He, J., & Jin, Z. C. (2021). Calcium channel blockers improve prognosis of patients with coronavirus disease 2019 and hypertension. Chinese Medical Journal, 134(13), 1602–1609. https://doi.org/10.1097/CM9.0000000000001479
Singh, A. K., Gupta, R., & Misra, A. (2020). Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14(4), 283-287. https://doi.org/https://doi.org/10.1016/j.dsx.2020.03.016
Yan, Y., Yang, Y., Wang, F., Ren, H., Zhang, S., Shi, X., ... & Dong, K. (2020). Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diabetes Research and Care, 8(1), e001343. https://doi.org/10.1136/bmjdrc-2020-001343
Ye, C., Zhang, S., Zhang, X., Cai, H., Gu, J., Lian, J., Lu, Y., Jia, H., Hu, J., Jin, C., Yu, G., Zhang, Y., Sheng, J., & Yang, Y. (2020). Impact of comorbidities on patients with COVID-19: A large retrospective study in Zhejiang, China. Journal of Medical Virology, 92(11), 2821–2829. https://doi.org/10.1002/jmv.26183
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 The Malaysian Journal of Nursing (MJN)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
